Therapies empowering natural killer (NK) cells
Search documents
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
Accessnewswireยท 2025-11-19 13:00
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower natural killer (NK) cells to seek and destroy malignant cells. ...